Peptide epitopes as biomarkers of soya sensitization in rBet v 1 immunotherapy of birch‐related soya allergy

摘要

Abstract Background There are no diagnostic and/or prognostic markers of the treatment outcome in patients receiving allergen immunotherapy (AIT). Although numerous allergen epitopes are known, their value in this context has not been investigated. This paper deals with re‐evaluation of sera from patients who underwent AIT against rBet v 1 for treatment of their soya allergy (BASALIT trial). Objective To evaluate the diagnostic and/or prognostic potential of allergen epitopes recognition by antibodies from patients with birch‐related soya allergy before and after rBet v 1‐immunotherapy. Methods PR‐10 epitope‐binding profiles from 34 patients were identified in silico using a statistical peptide phage display at start and at end of AIT. IgE‐ and IgG‐binding to these peptide epitopes was measured in peptide microarrays. Clinical relevance of epitopes was evaluated by comparing these measurements to a number of treatment outcome measures recorded during double‐blind placebo‐controlled food challenge at start and end of AIT. Results We showed that IgG‐ and IgE‐recognition of peptide epitopes after AIT were surrogate markers of 5 out of 12 analysed treatment outcome measures using this patient cohort. Seven epitopes were identified from multiple PR‐10 allergen sequences. Twenty‐six peptide epitopes were used for IgG and IgE measurements. IgE‐binding to one of the epitopes was associated with stronger intensity of oral tingling/itching after ingesting soya at start of AIT. IgG recognizing two other epitopes at start of AIT could predict decreased Cor a 1‐specific IgE concentration (p?=?.043) and decreased lip swelling intensity (p?=?.016) after AIT. Tolerance to increasing amounts of soy at food challenge correlated with IgG‐binding to another epitope at start of AIT (p?=?.046). Conclusion IgG‐ and IgE‐binding to peptide epitopes in PR‐10 is a potential indicator of the outcome and clinical course of AIT of soya‐sensitized patients with rBet v 1.